Literature DB >> 8953099

In vitro susceptibility of anaerobes to quinolones in the United States.

D W Hecht1, H M Wexler.   

Abstract

The in vitro activity of early fluoroquinolone antibodies--including ciprofloxacin, ofloxacin, fleroxacin, pefloxacin, enoxacin, and lomefloxacin--against most anaerobes has been limited, a characteristic making them poor choices as antianaerobic agents. Newer fluoroquinolones, including levofloxacin, sparfloxacin, and grepafloxacin, have moderate activity against anaerobes, including the Bacteroides fragilis group as well as Clostridium, Peptostreptococcus, Prevotella, and Fusobacterium species. Fluoroquinolones that demonstrate the greatest activity against the B. fragilis group and other anaerobes include DU-6859a, clinafloxacin, and the related naphthyridone, trovafloxacin. There has been wide variation in the susceptibility results among different studies testing the same antibiotic; such variation may be due in part to the use of different methodologies, inoculum sizes, and testing media. In a direct comparison of susceptibility findings for ciprofloxacin, ofloxacin, and levofloxacin in three different media, we have determined that twofold dilution differences in minimum inhibitory concentration (MIC) values (MIC90, mode MIC, and geometric mean MIC) may occur in association with the choice of testing media. Thus, testing media should be considered when comparing results of different studies on the susceptibility of anaerobes to fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8953099     DOI: 10.1093/clinids/23.supplement_1.s2

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  12 in total

Review 1.  Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.

Authors:  C E Nord
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

2.  Genetic determinant of intrinsic quinolone resistance in Fusobacterium canifelinum.

Authors:  Georg Conrads; Diane M Citron; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase.

Authors:  Y Onodera; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Bactericidal activity and postantibiotic effect of levofloxacin against anaerobes.

Authors:  S L Pendland; M Diaz-Linares; K W Garey; J G Woodward; S Ryu; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  The new fluoroquinolones: A critical review.

Authors:  G G Zhanel; A Walkty; L Vercaigne; J A Karlowsky; J Embil; A S Gin; D J Hoban
Journal:  Can J Infect Dis       Date:  1999-05

Review 7.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1999       Impact factor: 9.546

8.  Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.

Authors:  J S Solomkin; S E Wilson; N V Christou; O D Rotstein; E P Dellinger; R S Bennion; R Pak; K Tack
Journal:  Ann Surg       Date:  2001-01       Impact factor: 12.969

9.  In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.

Authors:  D Milatovic; F J Schmitz; S Brisse; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

10.  Active efflux of norfloxacin by Bacteroides fragilis.

Authors:  S Miyamae; H Nikaido; Y Tanaka; F Yoshimura
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.